Press release
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
- Oravax's virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta - Oravax signs licensing deal for VLP injectable vaccine
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"- Oravax's virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta\n - Oravax signs licensing deal for VLP injectable vaccine technology with Premas Biotech for commercialization in India\n\n\nNEW YORK, July 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced several updates for its majority-owned company Oravax Medical Inc.\nOravax capitalizes on Oramed's proprietary protein oral delivery (POD™) technology in the development of oral vaccines that are now only available via injection. Oravax is the exclusive owner of a virus-like particle (VLP) vaccine technology that targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially effective against current and future variants of the COVID-19 virus. The VLP vaccine is being tested in preclinical studies against COVID-19 variants including the Delta variant. Oravax's VLP vaccine technology is highly scalable with a low cost of goods and easily transferable. \nClinical Trial of Oral COVID-19 Vaccine Moving Forward\nOravax is gearing up to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally. The study protocol has been approved by the Institutional Review Board (IRB) at Ichilov Hospital in Tel Aviv, Israel and is now pending approval from the Israeli Ministry of Health. GMP manufacturing for the oral vaccine is under way. \nThe oral VLP COVID-19 vaccine is being developed for use both as a standalone vaccine as well as a booster for people who have been previously vaccinated for COVID-19. Experts including at the World Health Organization expect booster shots will be needed for both general and at-risk populations. If successful, an oral vaccine would offer enormous logistical, financial, and environmental benefits for the billions of people slated to receive them, particularly in parts of the world where access to healthcare is limited. \n\"Our vaccine is a particularly strong candidate against the evolving COVID-19 virus due to its unique targeting of three proteins rather than one. With the Delta and other variants proving a challenge to health admini...